Skip to main content

A new look at irritable bowel syndrome [IBS]: A neuroenteric disorder

Abstract

Irritable bowel syndrome is difficult to treat because of poorly defined pathophysiology, lack of diagnostic marker, and until recently, limited pharmacotherapy. After diagnosis, treatment includes diet and behavior modifications, along with pharmacologic treatment for mild disease and severe cases.

This is a preview of subscription content, access via your institution.

References

  1. Vanderwinden JM. Pyloric stenosis. N Engl J Med. 1992;327:511–515.

    PubMed  CAS  Article  Google Scholar 

  2. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45 Suppl II: 43–47.

    Google Scholar 

  3. Frissora C, Harris L. Choosing the appropriate oral contraceptive is part of the treatment of functional nausea in women [Abstract]. Am J Gastroenterol. 2001;96.

  4. American Gastroenterological Association. Medical position statement: irritable bowel syndrome. Gastroenterology. 1997; 112:2118–2119.

    Article  Google Scholar 

  5. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000; 46:78–82.

    PubMed  Article  CAS  Google Scholar 

  6. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of the irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654–660.

    PubMed  Article  CAS  Google Scholar 

  7. Talley NJ, Zinsmeister AR, Melton LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol. 1995;142:76–83.

    PubMed  CAS  Google Scholar 

  8. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–1580.

    PubMed  Article  CAS  Google Scholar 

  9. Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995;109:40–52.

    PubMed  Article  CAS  Google Scholar 

  10. McKendrick W, Read NW. Irritable bowel syndrome—post salmonella infection. J Infection. 1994;29:1–3.

    Article  CAS  Google Scholar 

  11. Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol. 2002;97:104–108.

    PubMed  Article  CAS  Google Scholar 

  12. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997;112:2120–2137.

    PubMed  Article  CAS  Google Scholar 

  13. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989;96:981–988.

    PubMed  CAS  Google Scholar 

  14. Green PHR, Stavropolos SN, Panagi SN, et al. Characteristics of adult celiac disease in the United States. Am J Gastroenterol. 2001;96:126–131.

    PubMed  Article  Google Scholar 

  15. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet. 1987;1:963–965.

    PubMed  Article  CAS  Google Scholar 

  16. Levy RL, VonKorff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome in patients in a health maintenance organization. Am J Gastroenterol. 2001;96:3122–3129.

    PubMed  Article  CAS  Google Scholar 

  17. Periti P, Tonelli F. Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii. J. Chemo. 2001;13(5):529–549.

    Google Scholar 

  18. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149–1159.

    PubMed  Article  CAS  Google Scholar 

  19. Frissora CL. Bupropion (Wellbutrin) for smoking cessation increases well being in IBS patients [abstract]. J Gastroenterol. 2002; 97(9). In press.

  20. DePonti R, Malagelada JR. Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management. Pharmacol Ther. 1998;80:49–88.

    Article  CAS  Google Scholar 

  21. Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in the irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7:87–92.

    PubMed  CAS  Article  Google Scholar 

  22. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea—predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2662–2670.

    PubMed  Article  CAS  Google Scholar 

  23. Wolfe SG, Chey WY, Washington MK, et al. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol. 2001;96:803–811.

    PubMed  Article  CAS  Google Scholar 

  24. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5HT4 receptor partial agonist relieves symptoms in irritable bowel patient with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15:1655–1666.

    PubMed  Article  CAS  Google Scholar 

  25. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of the irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:499–510.

    PubMed  CAS  Article  Google Scholar 

  26. Clouse RE, Lustman PJ, Geisman RA, et al. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther. 1994; 8:409–416.

    PubMed  CAS  Article  Google Scholar 

  27. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. 1992;116:1009–1016.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

The author has stated that she is a consultant and speaker for Astra-Zeneca, Biocodex, GlaxoSmithKline, Novartis, and Wyeth.

About this article

Cite this article

Frissora, C.L. A new look at irritable bowel syndrome [IBS]: A neuroenteric disorder. Compr Ther 28, 222–231 (2002). https://doi.org/10.1007/s12019-002-0031-y

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12019-002-0031-y

Keywords

  • Inflammatory Bowel Disease
  • Irritable Bowel Syndrome
  • Bupropion
  • Enteric Nervous System
  • Bacterial Overgrowth